Transmedics Group Inc (TMDX)
65.71  -1.65 (-2.45%)

Transmedics Group Inc is a biotechnology company focused on revolutionizing the organ transplant process through innovative medical technologies. They have developed a unique organ preservation and transportation system that optimizes the viability of donor organs, specifically targeting hearts, lungs, and livers. By employing advanced perfusion technology, Transmedics aims to improve patient outcomes and increase the availability of transplantable organs, ultimately addressing the critical shortages faced in the transplant community. Their commitment to enhancing the transplant experience positions them as a leader in the field of organ transplantation.

SummaryNewsPress ReleasesChartHistorical
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into TransMedics Group, Inc. (NASDAQ: TMDX)
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether TransMedics Group, Inc. (“TransMedics Group” or the “Company”) (NASDAQ: TMDX) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws.
By Scott+Scott Attorneys at Law LLP · Via Business Wire · November 7, 2024
TMDX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving TransMedics Group, Inc. (NASDAQ: TMDX) focused on whether the company and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.
By Robbins Geller Rudman & Dowd LLP · Via Business Wire · October 30, 2024
INVESTIGATION ALERT (NASDAQ:TMDX): DiCello Levitt LLP Is Investigating Investor Claims Against TransMedics Group, Inc. and Encourages TMDX Investors with Losses to Contact the Firm
SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- DiCello Levitt LLP announces that it is investigating whether TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ:TMDX) complied with federal securities laws. The Firm’s investigation focuses on whether the Company violated the federal securities laws, issued false and/or misleading statements, and/or failed to disclose information required to be disclosed to investors.
By DiCello Levitt LLP · Via GlobeNewswire · October 28, 2024
TransMedics Group Inc. (NASDAQ: TMDX) is a Leading Gainer in 11/7 Morning Trading
TransMedics Group, Inc. (NASDAQ: TMDX) is one of today’s top gainers. The company’s shares have moved -3.32% on the day to $36.71.
Via Investor Brand Network · November 7, 2023
TransMedics Group Inc. (NASDAQ: TMDX) is a Stock Spotlight on 5/12
TransMedics Group, Inc. (NASDAQ: TMDX) is the focus of IBN’s latest stock spotlight. The company’s shares have moved -1.75% on the day to $75.72.
Via Investor Brand Network · May 12, 2023
TRANSMEDICS ALERT: Bragar Eagel & Squire, P.C. is Investigating TransMedics Group, Inc. on Behalf of TransMedics Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX) on behalf of TransMedics stockholders. Our investigation concerns whether TransMedics has violated the federal securities laws and/or engaged in other unlawful business practices.
By Bragar Eagel & Squire · Via GlobeNewswire · February 27, 2024
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation – TMDX
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) resulting from allegations that TransMedics may have issued materially misleading business information to the investing public.
By The Rosen Law Firm, P.A. · Via Business Wire · February 26, 2024
New Innovation-Themed Whitepaper to Debut at the February 1st Emerald Groundhog Day Investment Forum
The investment team at Emerald believes that “Innovation Starts Small” – and are debuting a new whitepaper detailing the innovation-led investment opportunities in small-cap companies at their annual investment forum on February 1st. The 2024 Emerald Asset Management Groundhog Day Investment Forum is being held on Thursday, February 1st in suburban Philadelphia at The Valley Forge Sheraton – and online as an all-event virtual stream.
By Emerald Asset Management PA, LLC · Via Business Wire · January 29, 2024
TransMedics Group Inc. (NASDAQ: TMDX) is a Stock Spotlight on 4/28
TransMedics Group, Inc. (NASDAQ: TMDX) is the focus of IBN’s latest stock spotlight. The company’s shares have moved 0.38% on the day to $78.9.
Via Investor Brand Network · April 28, 2023
Investment Opportunities in the Innovation Economy Headline the 2024 Emerald Groundhog Day Investment Forum
Finding compelling innovation-led investment opportunities in U.S. small-cap stocks will be the theme of the 2024 Emerald Asset Management Groundhog Day Investment Forum, coming up on Thursday, February 1st at The Valley Forge Sheraton – and online as an all-event virtual stream. Emerald’s team of analysts and portfolio managers will focus on sector- and industry- specific opportunities as they introduce an exclusive new whitepaper on the Innovation Economy.
By Emerald Asset Management PA, LLC · Via Business Wire · January 22, 2024
TransMedics Group Inc. (NASDAQ: TMDX) Making Surprising Moves in Friday Session
TransMedics Group, Inc. (NASDAQ: TMDX) has caught the attention of the investment community today with its bullish price action. The company’s shares are currently up 13.76% on the day to $89.92.
Via Investor Brand Network · April 21, 2023
TransMedics to Present at Upcoming March Investor Conferences
ANDOVER, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the Cowen 43rd Annual Healthcare Conference in Boston on Monday, March 6, 2023, at 9:10 a.m. EST and to present virtually at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 12:00 p.m. EST.
By TransMedics · Via GlobeNewswire · February 21, 2023
S&P 500 Component DexCom Set For Further Price, Earnings Growth
Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023.
Via MarketBeat · November 13, 2022
Can Mid-Cap Lantheus Continue its 2022 Outperformance?
Mid-cap Lantheus Holdings has been on a revenue growth spurt boosted by a new product called Pylarify, which helps detect prostate cancer in an imaging test.
Via MarketBeat · October 28, 2022